This case study examines whether the United States should legalize the importation of lower-cost pharmaceuticals from abroad. It argues that importation should be permitted from countries with FDA-equivalent manufacturing and safety standards, and that pharmacists and wholesalers — rather than individual consumers — should serve as importation agents to preserve regulatory oversight and competitive pricing. The paper also considers which drug categories should qualify, recommending that certain high-risk products — such as controlled substances, biological products, and drugs under FDA Risk Evaluation and Mitigation Strategies — remain excluded, while currently marketed pharmaceuticals become eligible for importation.
The paper effectively uses a two-part case study structure, responding to each policy question with a thesis-first approach followed by supporting reasoning. This mirrors applied policy analysis, where a clear recommendation precedes justification. The author also anticipates counterarguments — such as the risks of individual importation — and addresses them directly, which strengthens the overall argument.
The paper is divided into two main policy questions, each functioning as a mini-essay. The first addresses legalization and who should be permitted to import; the second addresses the scope of eligible pharmaceuticals. Each section opens with a position statement, develops supporting reasons, and cites FDA regulatory criteria or cost data. A shared reference list closes the paper.
The United States should legalize the importation of lower-cost pharmaceuticals from selected countries with testing and licensure requirements similar to those of the FDA. Strict conformity to US standards for handling and manufacturing prescriptions would ensure that Americans are protected from unsafe medication. Importation would also lower drug prices for American consumers, as assessments have indicated that prescription drugs in countries like Canada retail at between 40 and 60 percent less than in the US. Ultimately, this would result in significant cost savings for individual customers as well as private and public payers. For instance, the state of Florida projects that its importation program would save the state between $80 and $150 million in prescription expenses annually (Freed et al., 2021).
Current importation laws only allow pharmaceutical companies to import drugs into the US. In essence, this means that manufacturers set their own drug prices in the American market. However, this creates a monopoly among manufacturers that limits price competition and encourages price gouging. For instance, the case of Turing Pharmaceuticals demonstrates how a company purchased the drug Daraprim and raised its price overnight from $13.50 to $750. A more beneficial importation plan would allow pharmacists and wholesalers to also import pharmaceuticals from pre-determined countries, subject to the FDA's safeguards and standards. This would eliminate the monopoly that manufacturers enjoy as sole importers and encourage price competition.
Allowing individuals to serve as importation agents, however, may be detrimental. It would impose a significant burden on the FDA in terms of ensuring safety and would make it difficult to control domestic medication prices. Moreover, allowing individual importers may make it more challenging for manufacturers to track their drugs in the market, which would increase the risk of counterfeiting (Freed et al., 2021).
The United States should permit the importation of only some pharmaceuticals, rather than all, for two major reasons. First, limiting the scope of eligible pharmaceuticals makes the process easier to manage and allows the FDA to maintain high levels of effectiveness in ensuring safety. Opening importation to only a defined set of pharmaceuticals would make it more manageable for the FDA to verify that all safety standards and regulations are consistently met.
Second, a scenario in which all pharmaceuticals are open to importation may significantly increase the FDA's workload, potentially forcing the agency to expand staffing levels or raise fees and licensing costs for importers. These additional costs would ultimately be passed on to consumers, thereby eroding the very cost savings that importation was intended to achieve.
Legalizing pharmaceutical importation from countries with FDA-equivalent manufacturing and safety standards offers a viable path to reducing prescription drug costs for American consumers. To be effective and safe, importation rights should be limited to pharmacists and wholesalers — not individual consumers — and high-risk drug categories, including controlled substances, biological products, and REMS-classified drugs, should remain excluded. This targeted approach balances the goals of affordability and safety while preserving the FDA's capacity to provide adequate regulatory oversight.
Freed, M., Neuman, T., & Cubanski, J. (2021). 10 FAQs on prescription drug importation. Kaiser Family Foundation. https://www.kff.org/medicare/issue-brief/10-faqs-on-prescription-drug-importation
Always verify citation format against your institution’s current style guide requirements.